AU5551190A - Method of inhibiting induction of latent or chronic viral infections - Google Patents

Method of inhibiting induction of latent or chronic viral infections

Info

Publication number
AU5551190A
AU5551190A AU55511/90A AU5551190A AU5551190A AU 5551190 A AU5551190 A AU 5551190A AU 55511/90 A AU55511/90 A AU 55511/90A AU 5551190 A AU5551190 A AU 5551190A AU 5551190 A AU5551190 A AU 5551190A
Authority
AU
Australia
Prior art keywords
oligomer
virus
nucleosides
viral
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55511/90A
Other languages
English (en)
Inventor
Jeffrey Laurence
Paul S. Miller
Paul O.P. Ts'o
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Johns Hopkins University
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of AU5551190A publication Critical patent/AU5551190A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU55511/90A 1989-04-21 1990-04-19 Method of inhibiting induction of latent or chronic viral infections Abandoned AU5551190A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34150889A 1989-04-21 1989-04-21
US341508 1989-04-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU64651/94A Division AU6465194A (en) 1989-04-21 1994-06-09 Method of inhibiting induction of latent or chronic viral infections

Publications (1)

Publication Number Publication Date
AU5551190A true AU5551190A (en) 1990-11-16

Family

ID=23337878

Family Applications (2)

Application Number Title Priority Date Filing Date
AU55511/90A Abandoned AU5551190A (en) 1989-04-21 1990-04-19 Method of inhibiting induction of latent or chronic viral infections
AU64651/94A Abandoned AU6465194A (en) 1989-04-21 1994-06-09 Method of inhibiting induction of latent or chronic viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU64651/94A Abandoned AU6465194A (en) 1989-04-21 1994-06-09 Method of inhibiting induction of latent or chronic viral infections

Country Status (7)

Country Link
EP (1) EP0469080A4 (ja)
JP (1) JPH04505615A (ja)
KR (1) KR920700654A (ja)
AU (2) AU5551190A (ja)
CA (1) CA2014990A1 (ja)
WO (1) WO1990012578A1 (ja)
ZA (1) ZA902912B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
KR100991975B1 (ko) * 2001-05-16 2010-11-04 미게닉스 인코포레이티드 핵산을 기본으로 하는 화합물 및 이의 사용방법
RU2207876C1 (ru) * 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4757055A (en) * 1980-11-12 1988-07-12 The Johns Hopkins University Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides

Also Published As

Publication number Publication date
ZA902912B (en) 1991-01-30
AU6465194A (en) 1994-10-06
CA2014990A1 (en) 1990-10-21
KR920700654A (ko) 1992-08-10
EP0469080A1 (en) 1992-02-05
EP0469080A4 (en) 1992-04-29
JPH04505615A (ja) 1992-10-01
WO1990012578A1 (en) 1990-11-01

Similar Documents

Publication Publication Date Title
Montano et al. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes
EP0412964B1 (en) Inhibition of htlv-iii by exogenous oligonucleotides
Rosen et al. Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III
Okamoto et al. Demonstration of virus-specific transcriptional activator (s) in cells infected with HTLV-III by an in vitro cell-free system
Woffendin et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells.
Harrich et al. Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat
Paca-Uccaralertkun et al. In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax
US5166195A (en) Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
Brighty et al. A cis-acting repressive sequence that overlaps the Rev-responsive element of human immunodeficiency virus type 1 regulates nuclear retention of env mRNAs independently of known splice signals.
Estable et al. Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity
Michael et al. Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities
EP0402402B1 (en) Inhibition of htlv-iii by exogenous oligonucleotides
US5821046A (en) RNA oligonucleotides that bind HIV tat protein
Sharmeen et al. Tat-dependent adenosine-to-inosine modification of wild-type transactivation response RNA.
Belshan et al. Biological characterization of Rev variation in equine infectious anemia virus
Sakuragi et al. Dissociation of genome dimerization from packaging functions and virion maturation of human immunodeficiency virus type 1
Cereseto et al. Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines
Bohan et al. Sodium butyrate activates human immunodeficiency virus long terminal repeat—directed expression
Gutekunst et al. Transcription of the HIV-1 LTR is regulated by the density of DNA CpG methylation
Vigne et al. Transcription of visna virus during its lytic cycle: evidence for a sequential early and late gene expression
AU5551190A (en) Method of inhibiting induction of latent or chronic viral infections
US5622854A (en) Method and reagent for inhibiting T-cell leukemia virus replication
WO1994029479A9 (en) Oligonucleotides which inhibit hiv protease function
WO1992020813A1 (en) Assays for factors affecting circularization of dna, assays for factors affecting dna integration, factors, and uses thereof
Hart et al. A human chromosome 12-associated 83-kilodalton cellular protein specifically binds to the loop region of human immunodeficiency virus type 1 trans-activation response element RNA